Form D · Biotechnology
Protea Biosciences Group, Inc.
Morgantown, WV · CIK 0001335103
Offering snapshot reported Nov 17, 2016 · SEC filing
- Reported sold
- $632K Offering amount: $5M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Nov 3, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 17, 2016 | Initial | $631,680 | No comparison | 25 | SEC filing |
| Jun 6, 2016 | Initial | $691,000 | No comparison | 14 | SEC filing |
| Sep 11, 2015 | Initial | $452,500 | No comparison | 8 | SEC filing |
| Jun 5, 2015 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Nov 14, 2014 | Initial | $4,426,528 | No comparison | 57 | SEC filing |
| Apr 17, 2014 | Initial | $600,000 | No comparison | 1 | SEC filing |
| Apr 17, 2014 | Initial | $175,000 | No comparison | 1 | SEC filing |
| Oct 30, 2013 | Initial | $275,000 | No comparison | 2 | SEC filing |
| Oct 23, 2013 | Initial | $700,000 | No comparison | 6 | SEC filing |
| Sep 5, 2013 | Initial | $345,000 | No comparison | 3 | SEC filing |
| Jul 29, 2013 | Initial | $439,500 | No comparison | 8 | SEC filing |
| Apr 25, 2013 | Initial | $680,000 | No comparison | 5 | SEC filing |
| Dec 27, 2012 | Initial | $0 | No comparison | 0 | SEC filing |
| Dec 14, 2012 | Initial | $915,000 | No comparison | 6 | SEC filing |
| Sep 6, 2012 | Initial | $450,000 | No comparison | 5 | SEC filing |
| May 9, 2012 | Initial | $305,000 | No comparison | 0 | SEC filing |
| Jan 10, 2012 | Initial | $280,000 | No comparison | 10 | SEC filing |
| Nov 23, 2011 | Initial | $200,000 | No comparison | 2 | SEC filing |
| Sep 16, 2011 | Initial | $0 | No comparison | 206 | SEC filing |
| Jun 19, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $95.8K
- Finders' fees
- $0
- Form D file number
- 021-274750
Included in the sales commission is a non-accountable expense allowance. Laidlaw also received three-year warrants to purchase 2,278,720 shares of common stock of the Issuer, with an exercise price of $0.09 per share.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Laidlaw & Company (UK) Ltd. | 119037 |
Source: Form D, filed Nov 17, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steve Antoline | Director |
| Josiah T. Austin | Director |
| Alessandro Baldi | Executive |
| Tom Clark | Director |
| Daniel Flynn | Director |
| Patrick Gallagher | Director |
| David Halverson | Executive |
| Steve Harris | Director |
| Leonard Harris | Director |
| Stanley Hostler | Director, Executive |
| Edward Hughes | Executive |
| Roderick Jackson | Director |
| Greg Kilby | Executive |
| Gregory Kilby | Executive |
| Steve O'loughlin | Executive |
| Matthew Powell | Executive |
| Milan Puskar | Director |
| Ed Roberson | Director |
| Ed Robertson | Director |
| Scott Segal | Director |
| Maged Shenouda | Director |
| Johan (Thijs) M. Spoor | Director |
| Stephen A. Turner | Director, Executive |
| C. Andrew Zulauf | Director |
| Andrew Zulauf | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1311 Pineview Drive Suite 501
Morgantown, WV, 26505
Morgantown, WV, 26505